BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Daperno M, Armuzzi A, Danese S, Fries W, Liguori G, Orlando A, Papi C, Principi M, Rizzello F, Viscido A, Gionchetti P. Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. Gastroenterol Res Pract 2019;2019:3108025. [PMID: 31565051 DOI: 10.1155/2019/3108025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Biscaglia G, Piazzolla M, Cocomazzi F, Melchionda G, De Cata A, Bossa F, Palmieri O, Andriulli A. Landmarks for dual biological therapy in inflammatory bowel disease: lesson from two case reports of vedolizumab in combination with ustekinumab. European Journal of Gastroenterology & Hepatology 2020;32:1579-82. [DOI: 10.1097/meg.0000000000001919] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Viscido A, Capannolo A, Petroni R, Stefanelli G, Zerboni G, De Martinis M, Necozione S, Penco M, Frieri G, Latella G, Romano S. Association between Corrected QT Interval and C-Reactive Protein in Patients with Inflammatory Bowel Diseases. Medicina (Kaunas) 2020;56:E382. [PMID: 32751480 DOI: 10.3390/medicina56080382] [Reference Citation Analysis]
3 . Stellungnahme der DGVS zur Nutzenbewertung des GBA zum Wirkstoff Filgotinib (Anwendungsgebiet: Colitis Ulcerosa, vorbehandelte Patient*innen). Z Gastroenterol 2022;60:1047-50. [DOI: 10.1055/a-1851-7777] [Reference Citation Analysis]
4 Larussa T, Flauti D, Abenavoli L, Boccuto L, Suraci E, Marasco R, Imeneo M, Luzza F. The Reality of Patient-Reported Outcomes of Health-Related Quality of Life in an Italian Cohort of Patients with Inflammatory Bowel Disease: Results from a Cross-Sectional Study. J Clin Med 2020;9:E2416. [PMID: 32731482 DOI: 10.3390/jcm9082416] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Armuzzi A, Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. Dig Liver Dis 2021;53:803-8. [PMID: 33744172 DOI: 10.1016/j.dld.2021.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
6 Han Q, Tang HZ, Zou M, Zhao J, Wang L, Bian ZX, Li YH. Anti-inflammatory Efficacy of Combined Natural Alkaloid Berberine and S1PR Modulator Fingolimod at Low Doses in Ulcerative Colitis Preclinical Models. J Nat Prod 2020;83:1939-49. [PMID: 32432470 DOI: 10.1021/acs.jnatprod.0c00175] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]